Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That's affiliated with Medicare. That's why Vascepa is still covered.
DMC8,
I am on Medicare, but I think my NYSHIP RX program is separate from Medicare.
Dave
The last 4 weeks, we are averaging 626K shares traded, which is absurdly low. I can only speculate that whoever has been shorting the stock has ended their campaign, due to the stock price.
It just feels like we are in some sort of purgatory right now.
Antibluechip, Did a quick search on the B4G formulary code. Most common reason that this is done seems to be inadequate generic supply.
Sleven,
Dmc, do you mean Medicare?
The CVS deal of dropping Vascepa did not effect Medicare plans.
Hi @antibluechip, great to hear that you are still getting Vascepa under Brand for Generic program.
May I ask, is your New York State Health Insurance on Medicaid?
More Info on CVS Caremark: Just looked at the CVS Caremark Formulary for my New York State Health Insurance.
The Vascepa entry is listed with a Code: VASCEPA B4G
In the Legend, B4G is defined as: Brand for Generic medication; Brand-Name medication is dispensed at generic copayment.
This doesn't seem as if CVS has dropped Brand Name Vascepa. In fact it seems like a better deal.
Dave
Slow day at the Simply Wall Street office?
https://finance.yahoo.com/news/heres-why-were-not-concerned-110655793.html
North, I haven't.
Sleven,
# sleven, it seems there are a number of lawyers with that first and last name set forth in the order of admission pro hac vice issued by the Magistrate Judge in the New Jersey antitrust action. Have you ascertained/fixed which one, among those that have desirable qualifications and experience?
Readers here will find paragraphs 23-45 of the complaint particularly interesting. I have not read further yet.
Express Scripts is suing FTC, seeks to stop FTC investigation of facts that allegedly caused large losses in CVS and other pharmacies, PBMs, insurance companies. It says FTC should actually support attempts by Express Scripts to lower drug prices. A Constitutional issue is raised via allegation that FTC has no authority to issue its July Report, and demands that it be retracted and withdrawn.
Looks like both FTC and DOJ need to investigate the unfair competition, if not outright fraud, by which the generics have attempted to enter AMRN’s triglycerides reduction and CVD market. GEHA, the large government employees insurance company, is said to have “sold” its insurance plan covering Vascepa to Express Scripts in light of loss on bid to continue its coverage at CVS. My out of pocket cost for brand Vascepa has risen markedly from the $9-15 for a 3 month supply I paid for many years.
See https://www.evernorth.com/advocate
Evernorth is a subsidiary of Cigna. Suit was filed in Missouri.
Sorry! The video didn't post. UGG!
The Residual Cardiovascular Risk Manifesto Program in Spain that kicked off today (co-sponsored by Amarin) is part of a broader initiative to address the persistent cardiovascular risks that remain even after optimal treatment of traditional risk factors like high cholesterol and hypertension.
This program is part of the Residual Risk Reduction Initiative (R3i), which focuses on identifying and managing additional factors contributing to cardiovascular risk, such as triglyceride-rich lipoproteins, remnant cholesterol, and lipoprotein(a) see website here:
https://www.r3i.org/
The Manifesto and the presentation event were made possible thanks to the non-conditioning contribution of Amarin Corporation.
Watch the video Manifesto and help us spread it!
https://www.linkedin.com/feed/
Ok, sorry for the misunderstanding.
I was simply reporting the content of the study with respect to Reduce It & the continued challenges Amarin has with respect to acceptance of Reduce It across academia & cardiologists. Perhaps you could send your response to the authors who still maintain the Reduce It results were dubious and controversial. Unfortunately I have been wide awake the last 5 years and am well aware that the mineral oil issue is a red herring.
In the 5-years since REDUCE-IT and the 4-years since STRENGTH and the 3-years since EMA, the mineral oil conspiracy has been thoroughly debunked. Perhaps you’ve been asleep all that time. It should be apparent to any observer that JELIS, CHERRY, and RESPECT-EPA had consistent and dose dependent effectiveness in reducing MACE without a placebo. Furthermore, the FDA, EMA and Health Canada definitively rejected the MO theory.
https://academic.oup.com/eurheartjsupp/article/22/Supplement_J/J1/5918446
Event lines have clearly separated by 2 yrs ...overwhelming within 3 yrs .
Run a small trial with the same subgroup ( without the mineral oil placebo ) to confirm this data ...or at least a short trial with one cohort post MI on current SOC and a matching cohort post MI with current SOC plus Vascepa
NNT of 11 !!!!
Kiwi
Unfortunately this study denigrated the Reduce It results, raised the placebo issue & highlighted that because of the placebo issue the ESC downgraded the level of recommendation from IIa to IIb (not sure how impactful that downgrade actually is). No wonder BP funded this to trash Reduce IT.
From the report:
The positive findings of REDUCE-IT and the neutral findings of STRENGTH have sparked controversy and a range of hypotheses explaining the pronounced effect of EPA in REDUCE-IT, including the use of pure EPA, high dosage (4g/day) and potential adverse effects of the mineral oil placebo. Indeed, unlike the participants receiving EPA, those receiving the mineral oil placebo had significantly higher levels of triglycerides, LDL-C, and hsCRP after two years compared to baseline. The possible detrimental effect of the REDUCE-IT placebo could potentially explain half of the effect size observed in the trial. To clarify this issue, a new trial comparing icosapent ethyl with corn oil, or even the STRENGTH trial's active arm, would be relevant.
26
The 2021 ESC guidelines on cardiovascular prevention downgraded the level of recommendation for using icosapent ethyl in patients with hypertriglyceridemia from IIa to IIb given those discrepancies
https://www.sciencedirect.com/science/article/pii/S2667089524000439
Eligibility for marine omega-3 fatty acid supplementation after acute coronary syndromes
The interesting thing about this study is not the fact that 1/3 of the patients in this prospective observational Swiss study were eligible for VASCEPA®/VAZKEPA® (IPE) post ASC (according to ESC Guidelines), but the fact that ¼ of those patients on statins + EZETIMIBE was still eligible after 1-year of follow-up.
BTW: REDUCE-IT Prior ACS demonstrated a 37% RRR in MACE with an NNT of 11. In other words, CVD Risk Reduction is not “Just” about LDL-c reduction. There’s lots of Residual Risk to be addressed. “It’s the EPA Stupid!”
AMRN is ready to soar ....... with the turkeys. I have missed several weeks of checking in but thought I should see how much things have changed over the last 17 years. Lets see 2006 price share $1 and now its 60 pennies. Truly amazing stock. I give everyone here credit here for sticking it out keep it up !
Large Swiss study that appears totally funded by BPs; no funding reported by AMRN re use of IPE in study. Results reported from use of IPE on discharge from hospital of patients 1 year after affliction of first CVD. More details available than reported above.
30 pages if printed both sides.
Ram; I didn’t watch the game. Good for the Cards. Marvin Harrison was quite a good draft choice.
I don’t have cable or antenna. I didn’t want to pay for FUBOTV or Sunday Ticket. Very disappointed with streaming TV.
Besides I’m pretty busy around my place. Grape harvest is done. Wine is fermenting nicely…. :D)
When Aaron Donald retired, it seemed LA hasn’t been the same since. They’ll be back.
Congrats Nukem........ your AZ boys put a hurtin on the lowly Lambs.
if we print another ugly revenue number for the third q. the clock will be ticking on the remaining cash balance..it then becomes apparent that the puny EU near term revenue (Italy or no) will not beat the clock…IMHO, it’s “reformulation” or “China surprise”….if you like risk, you’re in the right stock….
Well if Italy declines to reimburse for Vazkepa then it's even less likely that Germany and France will ....so there goes any meaningful EU revenues in any time frame .
In which case your plan becomes the Hail Mary throw ...way down field .
Hopefully Italy will follow Spain ...and keep that play alive ( to continue the metaphor )
Kiwi
au contraire,,,Denner wins by capturing U.S market and engaging a big pharma partner for joint drug development….meaningful revenues out of EU is 5 years away with existing product….existing employees have all abandoned ship by then….
We already have patent protection ( a solid patent moat ) in the EU until 2039
Thanks Dar.....
Kiwi, Does your logic also hold for off label generic prescriptions?
Sleven,
you don’t understand the big view….with issuance of new patent, big pharma says now we have some upside with a solid patent moat…they put in say $300M and joint develop the new drug….split the economic package…this is how denner wins
Interesting pts however
1) Even if AMRN announced today they were going to go forward with the bio equivalent in 2 cap a day form ....a year to design and get FDA approval for the trial ..possibly another year to recruit and run the trial ...then around 9 mths for the FDA to approve ...for the Marine indication only .
2) If you are already prescribed Vascepa for the R-IT indication ( as I am ) it's very unlikely an MD would want the liability of prescribing you an off label bio equivalent for the same indication. .
3) FDA won't approve the R-IT indication first on the condition that AMRN run a trial later ....This is not an unmet medical need .
If we are praying for anything ....pray of Italy to reimburse on generous terms
Kiwi
If FDA approved a reformulation based on a small bio equivalence trial for the high trigs indication that would be enough for significant off label sales - the ramp up in revenue from Reduce-IT results to FDA approval shows this scenario & the 2 pull a day v 4 should be cheaper than what the generics can offer. So there might not be a need to do another outcomes study unless FDA granted the CVD label with the condition that Amarin does an outcome study as well. That would be karma after the Anchor debacle.
In any event we are looking into a crystal ball given there has been no public disclosure on the reformulation so we’re just left to hope and pray.
ramfan60, as I recall posts in the past concerning your question, I believe in a BB the shares purchased can only be 10% of the shares traded for the day. Therefore, the actual BB shares # would fluctuate day to day. But that's from memory from prior posts.
However, I looked and found the below information.
Share repurchase
Wikipedia
https://en.wikipedia.org › wiki › Share_repurchase
According to SEC Rule 10b-18, the issuer cannot purchase more than 25% of the average daily
Based on today's average volume of 1.326M shares they could purchase ~330K shares daily.
Of course they have to announce the BB , volume will increase, SP will rise and ultimately they will be able to buy less shares. I'm not sure what restrictions Cantor is held to as they are the middleman in obtaining the shares.
Others need to weigh in with more expert knowledge.
Any drug thats reformulated will need an FDA approved trial before being marketed .
The smallest trial would be a bioequivalence trial like UNCY ran on OLC which is a reformulated Fosrenol .
Even after that the FDA would probably want some kind of Outcome trial before authorizing for the reduction of cardiovascular event risk ...as opposed to simply lowering TG's
In that case ... several years and many millions of $ later .
Italy is basically make or break ....hopefully Italy will agree to reimburse
Kiwi
Laurant……wouldn’t issuance of the new patent and reformulation of the dose to 2 pills from 4 be bigger news?
Italy rejecting again would be bad because it doesn't bode well for France/Germany, which are supposedly more even more difficult to get positive reimbursement.
I'm hoping positive Italy news is the beginning of the stock comeback.
Did I imagine it or did one of our esteemed posters post something about if AMRN starts buying back stock that they can only buy back around 350K shares a day?
Denner better hope like heck after his 1.5 years of pretty darn poor performance with AMRN that Italy does not shoot us down. If they do its probably over honestly at that point. The last thing the company needs is another dagger to the gut at this time. Denner would need to be replaced at that point to salvage anything that is left to salvage. And he would never ever win another proxy again in his life nor should he.
Thanks! You beat me to it. I am Italian but I live in another country. 6 hours difference.
Laurent, Thanks.
Sleven,
Well Kiwi, be skeptical when studies are referenced...... who benefits by a favorable study on a Trillion dollar drug? Who sponsored said studies? Follow the money!
Let me know what you think of this presentation.
MarketEdge has had it under accumulation for over 2 months. We’ll see if it lasts.
Followers
|
1106
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
428944
|
Created
|
03/12/07
|
Type
|
Free
|
Moderators ziploc_1 zmanindc Number sleven |
AMARIN TICKER RELATED LINKS
Amarin Webpage
NASDAQ AMRN Quote
Y! Finance AMRN Landing Page
Seeking Alpha AMRN Landing Page
FinViz AMRN Landing Page
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |